What is the clinical evidence from this study?

Study design: Editorial. Population: Degenerative mitral regurgitation (n=314). Intervention: Mitral valve repair. Primary outcome: Moderate or greater mitral regurgitation recurrence at 2 years.

February 28, 2026Journal of the American College of Cardiology0 citationsOpen Access

Surgical Repair as a Reference Standard in Degenerative Mitral Regurgitation

PLPatrizio Lancellotti TSTadafumi Sugimoto RDRaluca Dulgheru

Key Result

Mitral valve repair in a selected cohort of patients with degenerative mitral regurgitation resulted in a 2-year all-cause mortality of 3.5% and a 13% rate of moderate or greater MR recurrence.

Structured PICO

Population

314 patients with degenerative mitral regurgitation (DMR) accompanied by mild or moderate tricuspid regurgitation, with preserved left ventricular ejection fraction and end-systolic dimensions

Intervention

Mitral valve repair (MVR)

Contemporary multicenter surgical cohorts demonstrate excellent early safety and 2-year durability for mitral valve repair in selected patients with degenerative mitral regurgitation, serving as a benchmark for transcatheter therapies.

Limitations

Outcomes were conditional on successful mitral valve repair, as patients requiring conversion to valve replacement were excluded.
The cohort does not define an all-comers surgical benchmark, but rather illustrates outcomes in a selected repair population.
Findings cannot be directly extrapolated to broader populations, such as high or prohibitive risk patients treated later in the disease course.
Patients requiring conversion to valve replacement were excluded from the analysis
Does not define an all-comers surgical benchmark, but illustrates outcomes in a selected repair population
Operative risk is not explicitly reported

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Lancellotti et al. (2026) conducted an editorial in Degenerative mitral regurgitation (n=314). Mitral valve repair was evaluated on Moderate or greater mitral regurgitation recurrence at 2 years. Mitral valve repair in a selected cohort of patients with degenerative mitral regurgitation resulted in a 2-year all-cause mortality of 3.5% and a 13% rate of moderate or greater MR recurrence.

synapsesocial.com/papers/6a025a829cddff7633412ce7 https://doi.org/10.1016/j.jacc.2026.01.032

Ask AI

Helpful

Bookmark

View Full Paper

February 28, 2026Journal of the American College of Cardiology0 citationsOpen Access

Surgical Repair as a Reference Standard in Degenerative Mitral Regurgitation

PLPatrizio Lancellotti TSTadafumi Sugimoto RDRaluca Dulgheru

Key Result

Mitral valve repair in a selected cohort of patients with degenerative mitral regurgitation resulted in a 2-year all-cause mortality of 3.5% and a 13% rate of moderate or greater MR recurrence.

Structured PICO

Population

314 patients with degenerative mitral regurgitation (DMR) accompanied by mild or moderate tricuspid regurgitation, with preserved left ventricular ejection fraction and end-systolic dimensions

Intervention

Mitral valve repair (MVR)

Limitations

Outcomes were conditional on successful mitral valve repair, as patients requiring conversion to valve replacement were excluded.
The cohort does not define an all-comers surgical benchmark, but rather illustrates outcomes in a selected repair population.
Findings cannot be directly extrapolated to broader populations, such as high or prohibitive risk patients treated later in the disease course.
Patients requiring conversion to valve replacement were excluded from the analysis
Does not define an all-comers surgical benchmark, but illustrates outcomes in a selected repair population
Operative risk is not explicitly reported

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

synapsesocial.com/papers/6a025a829cddff7633412ce7 https://doi.org/10.1016/j.jacc.2026.01.032

Ask AI

Helpful

Bookmark

View Full Paper